{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:00:06Z","timestamp":1777348806366,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.11.025","type":"journal-article","created":{"date-parts":[[2015,11,22]],"date-time":"2015-11-22T05:15:06Z","timestamp":1448169306000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen\u2014The first step toward a rationally designed anthrax vaccine"],"prefix":"10.1016","volume":"34","author":[{"given":"Ryan C.","family":"McComb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Martchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.11.025_bib0290","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0295","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","article-title":"Structure-based antigen design: a strategy for next generation vaccines","volume":"26","author":"Dormitzer","year":"2008","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0305","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2015.04.001","article-title":"Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design","volume":"11","author":"Kong","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0310","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0315","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMra1409755","article-title":"Clinical management of potential bioterrorism-related conditions","volume":"372","author":"Adalja","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0320","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tim.2014.02.012","article-title":"Anthrax lethal and edema toxins in anthrax pathogenesis","volume":"22","author":"Liu","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0325","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/08998280.2005.11928074","article-title":"Anthrax: a continuing concern in the era of bioterrorism","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0330","article-title":"First hours: bioterrorism agents","author":"Office of Public Health Preparedness and Response","year":"2013","journal-title":"Cent Dis Control Prev"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0335","series-title":"BioThrax (Anthrax Vaccine Adsorbed) Package Insert","author":"Emergent BioSolutions","year":"2012"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0340","series-title":"The anthrax vaccine: Is it safe? Does it work?","year":"2002"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0345","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1128\/CVI.05556-11","article-title":"Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis","volume":"19","author":"Bellanti","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0350","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0355","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0360","doi-asserted-by":"crossref","first-page":"e13849","DOI":"10.1371\/journal.pone.0013849","article-title":"Phase i study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults","volume":"5","author":"Brown","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0365","doi-asserted-by":"crossref","first-page":"e0130952","DOI":"10.1371\/journal.pone.0130952","article-title":"Immunization with a recombinant, pseudomonas fluorescens-expressed, mutant form of Bacillus anthracis-derived protective antigen protects rabbits from anthrax infection","volume":"10","author":"Reed","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0370","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/AEM.64.3.982-991.1998","article-title":"Purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis","volume":"64","author":"Farchaus","year":"1998","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0375","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and Immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0380","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jps.23422","article-title":"Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine","volume":"102","author":"D'Souza","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0385","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.vaccine.2008.05.023","article-title":"Domain specificity of the human antibody response to Bacillus anthracis protective antigen","volume":"26","author":"Reason","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0390","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/IAI.01254-08","article-title":"Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed","volume":"77","author":"Reason","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/CVI.00792-14","article-title":"Generation and characterization of human monoclonal antibodies targeting anthrax protective antigen following vaccination with a recombinant protective antigen vaccine","volume":"22","author":"Chi","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0400","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.vaccine.2015.03.037","article-title":"Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: a protective neutralizing epitope from Bacillus anthracis protective antigen","volume":"33","author":"Oscherwitz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0405","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0415","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.89.21.10277","article-title":"Anthrax toxin protective antigen is activated by a cell-surface protease with the sequence specificity and catalytic properties of furin","volume":"89","author":"Klimpel","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0420","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.1016\/S0021-9258(17)32036-7","article-title":"Anthrax protective antigen forms oligomers during intoxication of mammalian-cells","volume":"269","author":"Milne","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0425","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/toxins3080979","article-title":"Mechanism of lethal toxin neutralization by a human monoclonal antibody specific for the PA(20) region of Bacillus anthracis protective antigen","volume":"3","author":"Reason","year":"2011","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0430","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/653495","article-title":"Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge","volume":"202","author":"Crowe","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0435","doi-asserted-by":"crossref","first-page":"22090","DOI":"10.1074\/jbc.M010222200","article-title":"A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo","volume":"276","author":"Singh","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0440","doi-asserted-by":"crossref","first-page":"19103","DOI":"10.1016\/S0021-9258(19)47273-6","article-title":"A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo","volume":"264","author":"Singh","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0445","doi-asserted-by":"crossref","first-page":"25077","DOI":"10.1074\/jbc.M109.022061","article-title":"Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies","volume":"284","author":"Abboud","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0450","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1128\/IAI.00150-06","article-title":"A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1","volume":"74","author":"Rivera","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0455","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.062160399","article-title":"Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen","volume":"99","author":"Cunningham","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0460","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1073\/pnas.2436299100","article-title":"Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis","volume":"100","author":"Mourez","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0465","doi-asserted-by":"crossref","first-page":"29039","DOI":"10.1016\/S0021-9258(19)62010-7","article-title":"The chymotrypsin-sensitive site, Ffd315, in anthrax toxin protective antigen is required for translocation of lethal factor","volume":"269","author":"Singh","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0470","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/bi972657b","article-title":"Identification of residues lining the anthrax protective antigen channel","volume":"37","author":"Benson","year":"1998","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0475","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1021\/bi990792d","article-title":"Anthrax protective antigen: prepore-to-pore conversion","volume":"38","author":"Miller","year":"1999","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0480","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02763","article-title":"Crystal structure of a complex between anthrax toxin and its host cell receptor","volume":"430","author":"Santelli","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0485","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.bbrc.2006.01.080","article-title":"The 2 beta(2)-2 beta(3) loop of anthrax protective antigen contains a dominant neutralizing epitope","volume":"341","author":"Zhang","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0490","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1574-695X.2006.00114.x","article-title":"Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen","volume":"47","author":"Gubbins","year":"2006","journal-title":"Fems Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0495","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2008.08.031","article-title":"Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis","volume":"26","author":"Yin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0500","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imbio.2013.08.008","article-title":"Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine","volume":"219","author":"Yin","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0505","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/IAI.00358-09","article-title":"Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen","volume":"77","author":"Oscherwitz","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0510","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.4049\/jimmunol.1001749","article-title":"A synthetic peptide vaccine directed against the 2 beta 2-2 beta 3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax","volume":"185","author":"Oscherwitz","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0515","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1126\/science.109563","article-title":"Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax","volume":"292","author":"Sellman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0520","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF03402106","article-title":"Characterization of dominant-negative forms of anthrax protective antigen","volume":"9","author":"Yan","year":"2003","journal-title":"Mol Med"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0525","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1128\/IAI.72.11.6313-6317.2004","article-title":"Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies","volume":"72","author":"Brossier","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0530","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1128\/JB.183.6.2111-2116.2001","article-title":"Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin","volume":"183","author":"Mogridge","year":"2001","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0535","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1073\/pnas.0405405101","article-title":"Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation","volume":"101","author":"Lacy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0540","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/CVI.00145-10","article-title":"Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays","volume":"17","author":"Brady","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0545","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1099\/13500872-142-3-707","article-title":"Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies","volume":"142","author":"Little","year":"1996","journal-title":"Microbiology-UK"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0550","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/IAI.56.7.1807-1813.1988","article-title":"Production and characterization of monoclonal-antibodies to the protective antigen component of Bacillus\u2013Anthracis toxin","volume":"56","author":"Little","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0555","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1128\/IAI.00117-09","article-title":"Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen","volume":"77","author":"Kelly-Cirino","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0560","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/IAI.67.4.1860-1865.1999","article-title":"Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin","volume":"67","author":"Varughese","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0565","doi-asserted-by":"crossref","first-page":"30936","DOI":"10.1074\/jbc.M301154200","article-title":"Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody","volume":"278","author":"Rosovitz","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.11.025_bib0570","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/AAC.49.8.3414-3420.2005","article-title":"Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694","volume":"49","author":"Laffly","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15016679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15016679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T20:07:09Z","timestamp":1653595629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15016679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15016679"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen\u2014The first step toward a rationally designed anthrax vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}